Unresectable Rectal Adenocarcinoma
Quiénes somos
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
SX-682 y nivolumab para el tratamiento del cáncer colorrectal metastásico o irresecable con mutación del RAS, el ensayo STOPTRAFFIC-1
